Omalizumab 300mg

Omalizumab is a modern drug that represents recombinant humanized anti-IgE- monoclonal antibodies, used in the treatment of patients with severe persistent atopic bronchial asthma that can’t controlled by the inhaled corticosteroids. Nowadays, the official instruction on the use of this drug includes the provision that it can be used for the treatment of chronic urticaria. Omalizumab can be used as a third-line drug for the treatment of chronic urticaria (in combination with second-line antihistamines) after the failure of other treatment schemes.

Omalizumab is a drug that belongs to the group of immunosuppressants, used only for the treatment of severe forms of bronchial asthma.

The recommended drug dose for the treatment of chronic idiopathic urticaria is 300 mg subcutaneously every 4 weeks. Your doctor should periodically revise the need for continuing the treatment. Usually, the effect of Omalizumab can be noticed in the weeks (with the following increase).
Omalizumab can be used for the treatment of moderate to severe atopic bronchial asthma only after the failure of inhaled corticosteroids.

Note that you can start using the drug only if it was prescribed by the profile expert, offering the results of all necessary laboratory studies.
According to the clinical researches and real clinical practice, the efficiency of Omalizumab reaches 90%.
The use of Omalizumab can cause the following negative consequences: infiltrating at the place of injection, pain in the bones and joints, headache, vertigo, dermatitis, infectious diseases and helminth infections and anaphylactic reactions.
Treatment of bronchial asthma is a complex process that consists of taking the drugs, recommended by your doctor. Besides, you should remember the effectiveness of general measures: avoid inhaling too cold air and general hypothermia that promotes the development of colds. It is important to give up smoking and avoid the impact of harmful production factors.